EHA 2022 Conference Coverage
EHA 2022 Magrolimab in Combination With Azacitidine for Untreated Higher-Risk MDS: 5F9005 Phase 1b Study Results
By
EHA 2022 Conference Coverage
FEATURING
David Sallman
By
EHA 2022 Conference Coverage
FEATURING
David Sallman
Comments 0
Login to view comments.
Click here to Login
